140 related articles for article (PubMed ID: 29721379)
1. Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.
Berinstein NL; McNamara M; Nguyen A; Egan J; Wolf GT
Oncoimmunology; 2018; 7(5):e1423173. PubMed ID: 29721379
[TBL] [Abstract][Full Text] [Related]
2. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
Wolf GT; Moyer JS; Kaplan MJ; Newman JG; Egan JE; Berinstein NL; Whiteside TL
Onco Targets Ther; 2018; 11():3731-3746. PubMed ID: 29988729
[TBL] [Abstract][Full Text] [Related]
3. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Berinstein NL; Wolf GT; Naylor PH; Baltzer L; Egan JE; Brandwein HJ; Whiteside TL; Goldstein LC; El-Naggar A; Badoual C; Fridman WH; White JM; Hadden JW
Cancer Immunol Immunother; 2012 Jun; 61(6):771-82. PubMed ID: 22057678
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.
Wolf GT; Liu S; Bellile E; Sartor M; Rozek L; Thomas D; Nguyen A; Zarins K; McHugh JB;
Oral Oncol; 2020 Dec; 111():104928. PubMed ID: 32738599
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.
Liu S; Bellile E; Nguyen A; Zarins K; D'Silva N; Rozek L; Wolf GT; Sartor MA;
Oral Oncol; 2021 Dec; 123():105587. PubMed ID: 34717154
[TBL] [Abstract][Full Text] [Related]
6. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Whiteside TL; Butterfield LH; Naylor PH; Egan JE; Hadden JW; Baltzer L; Wolf GT; Berinstein NL
Cancer Immunol Immunother; 2012 Jun; 61(6):783-8. PubMed ID: 22109700
[TBL] [Abstract][Full Text] [Related]
7. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
[TBL] [Abstract][Full Text] [Related]
9. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro.
Egan JE; Quadrini KJ; Santiago-Schwarz F; Hadden JW; Brandwein HJ; Signorelli KL
J Immunother; 2007 Sep; 30(6):624-33. PubMed ID: 17667526
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma.
Dueñas-Gonzalez A; Verastegui E; Lopez-Graniel C; Gonzalez A; Mota A; Barrera-Franco JL; Meneses A; Chanona J; de la Garza J; Chavez-Blanco A; Hadden JW
Int Immunopharmacol; 2002 Jun; 2(7):1007-16. PubMed ID: 12188025
[TBL] [Abstract][Full Text] [Related]
11. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
[TBL] [Abstract][Full Text] [Related]
12. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.
Hadden J; Verastegui E; Barrera JL; Kurman M; Meneses A; Zinser JW; de la Garza J; Hadden E
Int Immunopharmacol; 2003 Aug; 3(8):1073-81. PubMed ID: 12860164
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
14. Immunodeficiency and cancer: prospects for correction.
Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1061-71. PubMed ID: 12860163
[TBL] [Abstract][Full Text] [Related]
15. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
16. IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans.
Hadden JW; Verastegui E; Hadden E
Ann N Y Acad Sci; 2007 Sep; 1112():245-55. PubMed ID: 17600288
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Freeman SM; Franco JL; Kenady DE; Baltzer L; Roth Z; Brandwein HJ; Hadden JW
Am J Clin Oncol; 2011 Apr; 34(2):173-8. PubMed ID: 20539208
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
20. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
